Regulatory FDA Approves First Non-Antipsychotic Drug to Treat Agitation Associated with Dementia FDAThe U.S.NeuroscienceRead full story pharminent April 30, 2026 (Last updated: May 1, 2026) FDA The U.S. Neuroscience Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Eligibility for Medicare Savings Programs for Specified Low-Income Medicare Beneficiaries (SLMBs)Next: Two biotechs raise a combined $556M in latest spurt of IPOs Related Stories Regulatory FDA approves MSD’s Keytruda combinations for MIBC pharminent July 13, 2026 Regulatory FDA freezes CRL trove as ‘radical transparency’ push hits speedbump pharminent July 9, 2026 Regulatory UK first in Europe to clear Boehringer’s IPF drug Jascayd pharminent July 9, 2026
